Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single-Center, Single Dose Study to Evaluate the Effect of Food, Gender, and Age on Safety and Pharmacokinetic Profiles of SUVN-911 Tablets Orally Administered in Healthy Subjects

Trial Profile

A Phase I, Single-Center, Single Dose Study to Evaluate the Effect of Food, Gender, and Age on Safety and Pharmacokinetic Profiles of SUVN-911 Tablets Orally Administered in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropanicant (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Suven Life Sciences

Most Recent Events

  • 13 Aug 2022 Results from two clinical studies (NCT03155503 and NCT03551288) assessing safety, tolerability and pharmacokinetics of ropanicant after single and multiple ascending doses in healthy subjects published in the Clinical Drug Investigation
  • 08 Aug 2018 Status changed from recruiting to completed.
  • 13 Jun 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top